Previous 10 | Next 10 |
2023-06-30 06:07:11 ET Stock index futures rose early Friday following strong U.S. economic data , which grew much more than initially thought in the first quarter. The focus is now on the U.S. personal consumption expenditures price index, or the Fed's favorite inflation ...
2023-06-29 11:33:30 ET Shares of BioXcel Therapeutics (NASDAQ: BTAI) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501. The stock is down more than 68% so far this year. BioXcel...
2023-06-29 10:10:59 ET Gainers: RenovoRx ( RNXT ) +37% . Immunome ( IMNM ) +36% . DermTech ( DMTK ) +15% . Galera Therapeutics ( GRTX ) +9% . Oncolytics Biotech ( ONCY ) +7% . Losers: BioXcel Therapeutics ( BTA...
2023-06-29 08:47:24 ET BioXcel Therapeutics ( BTAI ) -67% . announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation . CorMedix ( CRMD ) -21% on pricing $40M securities off...
2023-06-29 08:40:41 ET BioXcel Therapeutics ( NASDAQ: BTAI ) fell ~58% pre-market Thursday even after announcing that its Phase 3 trial for Alzheimer’s candidate BXCL501 reached its main goals as investors reacted to its data integrity issues. The conduct of a princip...
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at 2 hours (p=0.0112) Met key secondary endpoint with statistically significant reduction (p=0.0185) in agitat...
2023-05-28 21:07:53 ET Summary BioXcel has just published the results of the first part of the Serenity III trial in which, although clinically good results, it has not been able to achieve statistically significant. This first part of the trial has served the company to choose a ...
2023-05-25 12:40:13 ET Shares of BioXcel Therapeutics (NASDAQ: BTAI) were down more than 19% early Thursday afternoon after the biotech company released the first part of a phase 3 trial for the therapy BXCL501 (dexmedetomidine) to treat acute agitation in bipolar disorders or s...
2023-05-25 08:43:39 ET BioXcel Therapeutics ( NASDAQ: BTAI ) said the main efficacy goal was not statistically significant at 2 hours for its drug BXCL501 versus placebo in Part 1 of a phase 3 trial for acute treatment of bipolar disorders- or schizophrenia-associated agit...
Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™ Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates seen in SERENITY I and II BXCL501 was well tolerated and demo...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...